Key Takeaways
- • IGIS Asia Investment Management and CHA Bio Group announced a strategic partnership on February 16, 2023, to establish a pan-Asian life science real estate investment platform targeting the Asia-Pacific region, with initial focus on South Korea and metropolitan centers across the region.
- • IGIS Asia has launched a dedicated healthcare and life sciences real estate fund with a target of $350 million in assets under management during the initial phase, establishing the Korea Life Science Investment Platform (KLSIP) as its first Korea-focused investment vehicle.
- • The joint venture will develop and invest in high-quality life science assets including R&D facilities, manufacturing plants, hospitals, medical offices, and healthcare centers, serving clients ranging from biotechnology incubators to multinational pharmaceutical groups.
- • The partnership leverages IGIS's established track record in real estate transactions and CHA Bio Group's deep expertise in the biopharma industry to capture first-mover advantage in the emerging life science real estate sector across Asia-Pacific.
- • IGIS, the Singapore-based pan-Asian investment arm of South Korea's IGIS Asset Management (the country's largest real estate investment manager), positions this venture as a catalyst for accelerating life science sector growth across the region.
Summary
IGIS Asia Investment Management, the pan-Asian investment arm of South Korea's largest real estate investment manager, has partnered with CHA Bio Group, one of South Korea's largest and oldest biopharma conglomerates with significant global operations, to establish a dedicated life science real estate investment platform serving the Asia-Pacific region. The announcement was made on February 16, 2023, signaling a strategic entry into the underserved life sciences real estate sector across Asia-Pacific markets.
The partnership establishes a new investment vehicle designed to develop and deploy capital into high-quality life science infrastructure assets. The platform targets R&D facilities, manufacturing plants, hospitals, medical offices, and healthcare centers across metropolitan areas, particularly in South Korea and throughout the Asia-Pacific region. The venture positions itself to serve a broad spectrum of clients, from early-stage biotechnology incubators to established multinational pharmaceutical enterprises requiring specialized real estate solutions.
IGIS has concurrently launched a dedicated healthcare and life sciences real estate fund with an initial target of $350 million in assets under management. As part of this initiative, IGIS will establish the Korea Life Science Investment Platform (KLSIP), marking the first Korea-focused investment vehicle specifically dedicated to life science real estate. This capital will be deployed to develop facilities aligned with the accelerating demand within South Korea's growing life sciences sector.
The strategic rationale for the partnership centers on complementary competitive advantages: IGIS brings an established track record in executing complex real estate transactions and pan-regional deployment capabilities, while CHA Bio Group contributes deep domain expertise in the biopharma sector, regulatory knowledge, and industry relationships. Both parties view the venture as foundational infrastructure for catalyzing broader life science sector growth across Asia-Pacific, positioning them to capture first-mover advantage in this emerging real estate subsector as multinational and local life sciences companies seek specialized facilities in high-growth markets.
The partnership establishes a new investment vehicle designed to develop and deploy capital into high-quality life science infrastructure assets. The platform targets R&D facilities, manufacturing plants, hospitals, medical offices, and healthcare centers across metropolitan areas, particularly in South Korea and throughout the Asia-Pacific region. The venture positions itself to serve a broad spectrum of clients, from early-stage biotechnology incubators to established multinational pharmaceutical enterprises requiring specialized real estate solutions.
IGIS has concurrently launched a dedicated healthcare and life sciences real estate fund with an initial target of $350 million in assets under management. As part of this initiative, IGIS will establish the Korea Life Science Investment Platform (KLSIP), marking the first Korea-focused investment vehicle specifically dedicated to life science real estate. This capital will be deployed to develop facilities aligned with the accelerating demand within South Korea's growing life sciences sector.
The strategic rationale for the partnership centers on complementary competitive advantages: IGIS brings an established track record in executing complex real estate transactions and pan-regional deployment capabilities, while CHA Bio Group contributes deep domain expertise in the biopharma sector, regulatory knowledge, and industry relationships. Both parties view the venture as foundational infrastructure for catalyzing broader life science sector growth across Asia-Pacific, positioning them to capture first-mover advantage in this emerging real estate subsector as multinational and local life sciences companies seek specialized facilities in high-growth markets.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.